BioMedNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) CEO Discusses Substantial Scientific, Product Development Advances in Letter to Shareholders

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), earlier this year issued a letter to shareholders from its CEO Mark Dybul, MD, in which Dr. Dybul discussed scientific and product development advances and plans for the future. The advances included independently conducted studies that showed remarkably promising results, demonstrating and confirming proof-of-concept for the company’s cell-gene-immunotherapy for pancreatic cancer and, potentially, other solid tumors, as well as the accelerated timeline for submission of the company’s Pre-Investigational New Drug (“Pre-IND”) application to the U.S. FDA. “Despite significant challenges that would have derailed many companies, our strategic plan to focus on our most promising platform has allowed us to significantly de-risk our cancer immune oncology program and be in a strong position now. We have made substantial scientific and product development advances over the past 10 months. This was accomplished while substantially reducing operating costs – including, at my request, a decrease in my compensation as CEO – towards maximizing shareholder value,” Dr. Dybul wrote in the letter. “The progress with a platform that has key attributes that could potentially be leveraged for products to treat solid tumors, HIV and, perhaps, other infectious diseases is particularly encouraging.”

To view the full press release, visit https://ibn.fm/WALID

About Renovaro BioSciences Inc.

Renovaro BioSciences, formerly Enochian BioSciences Inc., is an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy. The company aims to unlock potentially long-term or life-long cancer remission in some of the deadliest cancers, and to potentially treat or cure serious infectious diseases such as human immunodeficiency virus (“HIV”) and hepatitis B virus (“HBV”) infection. For more information, visit the company’s website at https://enochianbio.com.

NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork